Savannah Demko

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial. The data, presented at ESMO Congress, showed the benefit seen after patients with hormone receptor-positive, HER2-negative breast cancer were off ribociclib (Kisqali, Novartis), Tolaney told Healio in a video interview.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.“In my mind, these data really establish T-DXd [Enhertu; AstraZeneca, Daichii Sankyo] as standard of care, not just for systemic disease in

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.The study showed the benefit of integrating ovarian function suppression with adjuvant endocrine therapy in premenopausal women with HR-positive, HER2-postive breast cancer.

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress. The study showed that neoadjuvant pembrolizumab (Keytruda, Merck) plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in OS compared with

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, discussed “interesting updates” from the NATALEE trial presented at ESMO Congress.The study showed the efficacy of adjuvant ribociclib (Kisqali, Novartis) plus nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress. Importantly, trastuzumab deruxtecan, also known as T-DXd, (Enhertu; AstraZeneca, Daiichi Sankyo) exhibited these benefits in a large cohort with stable and active

Breastfeeding appeared safe in women with hormone receptor–positive early breast cancer who temporarily interrupted treatment to attempt pregnancy, according to results from the POSITIVE trial presented at ESMO Congress. “I think that the main takeaway from this study is that women are motivated to breastfeed after a breast cancer diagnosis and interrupting treatment to have a child,

In a video interview with Healio, Chandrajit Raut, MD, MS, discussed highlights from “one of the best” Connective Tissue Oncology Society meetings he has attended. Raut, chief of surgical oncology at Brigham and Women’s Hospital, surgical director of the Dana-Farber Brigham Cancer Center sarcoma and bone oncology programs, and professor of surgery at Harvard Medical School,

Candace Haddox, MD, explored advances in genetic sequencing for sarcomas, which was a major theme of the Connective Tissue Oncology Society Annual Meeting, in this video interview with Healio.“We’re making progress on two key fronts: the first is gaining a better understanding of heterogeneity not only across sarcoma subtypes, but even within subtypes and within single patients;

In this video, Candace Haddox, MD, discussed a few presentations from the Connective Tissue Oncology Society Annual Meeting that focused on how better understanding of sarcoma biology could lead to clinical advancement.“We are seeing progress in understanding sarcoma biology and, importantly, we’re incorporating this knowledge into rational clinical trial and drug development that